June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Efficacy of rituximab in severe ocular cicatricial pemphigoid
Author Affiliations & Notes
  • Serge Doan
    Ophthalmology, Bichat Hospital & A de Rothschild Foundation, Paris, France
  • Sophie Stephan
    Ophthalmology, Bichat Hospital & A de Rothschild Foundation, Paris, France
  • Catherine Prost
    Dermatology, Avicenne Hospital, Bobigny, France
  • Marina Alexandre
    Dermatology, Avicenne Hospital, Bobigny, France
  • Isabelle Cochereau
    Ophthalmology, Bichat Hospital & A de Rothschild Foundation, Paris, France
  • Eric Gabison
    Ophthalmology, Bichat Hospital & A de Rothschild Foundation, Paris, France
  • Footnotes
    Commercial Relationships Serge Doan, None; Sophie Stephan, None; Catherine Prost, None; Marina Alexandre, None; Isabelle Cochereau, Laboratoires Thea (C), Laboratoires Thea (F), Allergan (C), Lux Bioscience (F); Eric Gabison, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2115. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Serge Doan, Sophie Stephan, Catherine Prost, Marina Alexandre, Isabelle Cochereau, Eric Gabison; Efficacy of rituximab in severe ocular cicatricial pemphigoid. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2115.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To report the efficacy of rituximab in patients with severe ocular cicatricial pemphigoid (OCP).

Methods: In this non controlled retrospective study, 18 patients with severe OCP (8 males, 10 females ; median age, 73 years ; 31 eyes) were treated with rituximab, because of toxicity or resistance to cyclophosphamide (in 10 and 4 cases, respectively), or of rapid evolutivity (4 cases). The treatment consisted of 4 weekly intravenous administrations (375 mg/m2) or 2 monthly intravenous administrations (1 gram). This treatment was repeated in case of persistent conjunctival inflammation. Complete remission was defined as the absence of conjunctival inflammation.

Results: Complete remission was obtained in 16 patients (89%) within a median period of 2.5 months (range, 1 to 6 months) after 1 or 2 treatments (in 12 and 4 patients, respectively). The disease recurred in 5 of the 16 patients after 6 to 27 months. Complete remission was obtained after an additional rituximab treatment. Median follow up without any recurrence was 21 months (range, 12 to 54 months). No serious adverse effect was noted.

Conclusions: Rituximab is a potent treatment of severe OCP. It is particularly interesting in case of resistance or contraindication to cyclophosphamide, or in rapidly evolutive forms.

Keywords: 432 autoimmune disease • 474 conjunctiva • 555 immunomodulation/immunoregulation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×